Johnson & Johnson (JNJ) has agreed to supply Coherus Oncology (CHRS) with its bispecific antibody pasritamig to evaluate a combination of it with Coherus’ monoclonal antibody tagmokitug for a phase 1b trial in metastatic castration-resistant prostate cancer.
